CA2690382A1 - Antibody formulations - Google Patents
Antibody formulations Download PDFInfo
- Publication number
- CA2690382A1 CA2690382A1 CA2690382A CA2690382A CA2690382A1 CA 2690382 A1 CA2690382 A1 CA 2690382A1 CA 2690382 A CA2690382 A CA 2690382A CA 2690382 A CA2690382 A CA 2690382A CA 2690382 A1 CA2690382 A1 CA 2690382A1
- Authority
- CA
- Canada
- Prior art keywords
- photon
- photon flux
- mode
- circuit
- counting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000004907 flux Effects 0.000 claims abstract description 45
- 238000003384 imaging method Methods 0.000 claims abstract description 38
- 230000005855 radiation Effects 0.000 claims abstract description 38
- 230000010354 integration Effects 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 16
- 238000012544 monitoring process Methods 0.000 claims abstract description 5
- 238000001514 detection method Methods 0.000 claims description 16
- 230000000052 comparative effect Effects 0.000 claims description 9
- 230000008859 change Effects 0.000 claims description 5
- 239000011669 selenium Substances 0.000 description 13
- 230000008901 benefit Effects 0.000 description 8
- 239000003990 capacitor Substances 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 229910052711 selenium Inorganic materials 0.000 description 5
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000004088 simulation Methods 0.000 description 4
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000005684 electric field Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000007493 shaping process Methods 0.000 description 3
- 206010073306 Exposure to radiation Diseases 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- QWUZMTJBRUASOW-UHFFFAOYSA-N cadmium tellanylidenezinc Chemical compound [Zn].[Cd].[Te] QWUZMTJBRUASOW-UHFFFAOYSA-N 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000005465 channeling Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000009607 mammography Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000003530 single readout Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94407607P | 2007-06-14 | 2007-06-14 | |
| US60/944,076 | 2007-06-14 | ||
| PCT/US2008/066928 WO2008157356A2 (en) | 2007-06-14 | 2008-06-13 | Antibody formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2690382A1 true CA2690382A1 (en) | 2008-12-24 |
Family
ID=39956053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2690382A Abandoned CA2690382A1 (en) | 2007-06-14 | 2008-06-13 | Antibody formulations |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20080311119A1 (OSRAM) |
| EP (2) | EP2170390B1 (OSRAM) |
| JP (2) | JP2010529999A (OSRAM) |
| CN (2) | CN103977404A (OSRAM) |
| AR (2) | AR067011A1 (OSRAM) |
| AU (1) | AU2008266051B2 (OSRAM) |
| BR (1) | BRPI0814252B8 (OSRAM) |
| CA (1) | CA2690382A1 (OSRAM) |
| CY (1) | CY1121208T1 (OSRAM) |
| DK (1) | DK2170390T3 (OSRAM) |
| EA (1) | EA020456B1 (OSRAM) |
| ES (1) | ES2707815T3 (OSRAM) |
| HR (1) | HRP20182146T1 (OSRAM) |
| HU (1) | HUE041555T2 (OSRAM) |
| IL (1) | IL202648B (OSRAM) |
| LT (1) | LT2170390T (OSRAM) |
| MX (2) | MX2009013593A (OSRAM) |
| NZ (2) | NZ582436A (OSRAM) |
| PL (1) | PL2170390T3 (OSRAM) |
| PT (1) | PT2170390T (OSRAM) |
| SI (1) | SI2170390T1 (OSRAM) |
| TR (1) | TR201820837T4 (OSRAM) |
| TW (1) | TWI614028B (OSRAM) |
| WO (1) | WO2008157356A2 (OSRAM) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2358763C2 (ru) | 2003-02-10 | 2009-06-20 | Элан Фармасьютикалз, Инк. | Композиции иммуноглобулина и способ их получения |
| CA2765220A1 (en) * | 2009-07-14 | 2011-01-20 | Biogen Idec Ma Inc. | Methods for inhibiting yellow color and peroxide formation in a composition |
| BR112012021576A2 (pt) | 2010-02-26 | 2016-10-25 | Novo Nordisk As | composições estáveis contendo anticorpo. |
| EA201892184A1 (ru) | 2010-03-01 | 2019-03-29 | БАЙЕР ХЕЛЬСКЕР ЛЛСи | Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора |
| EP4032912B1 (en) | 2010-04-16 | 2025-05-28 | Biogen MA Inc. | Anti-vla-4 antibodies |
| US20130136733A1 (en) | 2010-05-28 | 2013-05-30 | Novo Nordisk A/S | Stable Multi-Dose Compositions Comprising an Antibody and a Preservative |
| WO2013006461A1 (en) * | 2011-07-01 | 2013-01-10 | Biogen Idec Ma Inc. | Cholesterol-based media supplementals for cell culture |
| US9302002B2 (en) | 2011-10-18 | 2016-04-05 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with combinations of sugars and polyols |
| US10493151B2 (en) | 2011-10-18 | 2019-12-03 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with sodium chloride |
| AU2013221635B2 (en) * | 2012-02-16 | 2017-12-07 | Santarus, Inc. | Anti-VLA1 (CD49a) antibody pharmaceutical compositions |
| US20150150979A1 (en) * | 2012-06-21 | 2015-06-04 | Ucb Pharma, S.A. | Pharmaceutical formulation |
| CA2878508A1 (en) | 2012-07-09 | 2014-01-16 | Coherus Biosciences, Inc. | Etanercept formulations exhibiting marked reduction in sub-visible particles |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| PL2895188T3 (pl) | 2012-09-11 | 2018-06-29 | Coherus Biosciences, Inc. | Prawidłowo pofałdowany etanercept o wysokiej czystości i doskonałej wydajności |
| CN103217525B (zh) * | 2013-03-21 | 2015-04-29 | 上海执诚生物科技股份有限公司 | 一种含有提高胱抑素c胶乳包被抗体的稳定性的组合物、稳定剂及其制备方法和用途 |
| EP3062814A1 (en) * | 2013-10-29 | 2016-09-07 | Albumedix A/S | Antibody composition |
| CN105793850B (zh) * | 2013-11-29 | 2020-04-24 | 豪夫迈·罗氏有限公司 | 抗体选择装置和方法 |
| CA2938933A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
| WO2015136468A1 (en) * | 2014-03-13 | 2015-09-17 | Prothena Biosciences Limited | Combination treatment for multiple sclerosis |
| EP3149030A2 (en) * | 2014-06-02 | 2017-04-05 | Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme | Production of fc fragments |
| EP3207061A1 (en) * | 2014-10-18 | 2017-08-23 | Pfizer Inc | Anti-il-7r antibody compositions |
| WO2017205101A1 (en) | 2016-05-27 | 2017-11-30 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis |
| GB201612317D0 (en) | 2016-07-15 | 2016-08-31 | Philogen Spa | Antibody compositions |
| US11608357B2 (en) | 2018-08-28 | 2023-03-21 | Arecor Limited | Stabilized antibody protein solutions |
| GB201703062D0 (en) * | 2017-02-24 | 2017-04-12 | Arecor Ltd | Stabilized antibody protein solutions |
| EP3372242A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
| EP3372241A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| WO2018204374A1 (en) | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
| JP7518764B2 (ja) | 2017-10-26 | 2024-07-18 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 発作性夜間ヘモグロビン尿症（ＰＮＨ）および非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量および投与 |
| EP3773696A4 (en) * | 2018-04-10 | 2021-12-29 | Dr. Reddy's Laboratories Ltd. | Stable formulations of therapeutic antibody |
| CN119080931A (zh) | 2018-06-04 | 2024-12-06 | 马萨诸塞州渤健公司 | 具有降低的效应功能的抗vla-4抗体 |
| JP7538723B2 (ja) * | 2018-06-28 | 2024-08-22 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 抗ｃ５抗体の産生方法 |
| KR20210089215A (ko) | 2018-11-07 | 2021-07-15 | 머크 샤프 앤드 돔 코포레이션 | 항-lag3 항체 및 항-pd-1 항체의 공동-제제 |
| WO2021007504A2 (en) * | 2019-07-10 | 2021-01-14 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising reduced level of host cell proteins |
| CN113134081A (zh) * | 2020-01-20 | 2021-07-20 | 上海君实生物医药科技股份有限公司 | 抗btla抗体药物组合物及其用途 |
| WO2022092183A1 (ja) * | 2020-10-30 | 2022-05-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 医薬組成物 |
| MX2023005596A (es) | 2020-11-14 | 2023-08-15 | Biogen Ma Inc | Regímenes de dosificación bifásica subcutánea para anticuerpos anti-vla-4. |
| JP2024513974A (ja) | 2021-04-13 | 2024-03-27 | バイオジェン・エムエイ・インコーポレイテッド | 慢性活動性白質病変／放射線学的孤立性症候群を治療するための組成物及び方法 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4475196A (en) * | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) * | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) * | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) * | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) * | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) * | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) * | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| JPS62196921A (ja) | 1986-02-25 | 1987-08-31 | Nec Corp | 位相検出回路 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) * | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5312335A (en) * | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| EP0940468A1 (en) * | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| SG47043A1 (en) | 1993-01-06 | 1998-03-20 | Kinerton Ltd | Ionic molecular conjugates of biodegradeble polyesters and bioactive polypeptides |
| SG44845A1 (en) | 1993-01-12 | 1997-12-19 | Biogen Inc | Recombitant anti-vla4 antibody molecules |
| AU687790B2 (en) * | 1993-02-09 | 1998-03-05 | Biogen Idec Ma Inc. | Treatment for insulin dependent diabetes |
| US5827690A (en) * | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5840299A (en) * | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| AU703152B2 (en) * | 1994-01-25 | 1999-03-18 | Biogen Ma Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| DE19541844C1 (de) | 1995-11-09 | 1997-07-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung |
| DK0929578T3 (da) * | 1996-02-09 | 2003-08-25 | Abbott Lab Bermuda Ltd | Humane antistoffer, der binder human TNFalfa |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| WO2001055112A1 (en) | 2000-01-27 | 2001-08-02 | American Cyanamid Company | Method for preparing alpha-sulfonyl hydroxamic acid derivatives |
| US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
| RU2358763C2 (ru) * | 2003-02-10 | 2009-06-20 | Элан Фармасьютикалз, Инк. | Композиции иммуноглобулина и способ их получения |
| CA2478458A1 (en) | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
| CN101102792A (zh) * | 2004-11-19 | 2008-01-09 | 比奥根艾迪克Ma公司 | 治疗多发性硬化 |
| WO2008021954A2 (en) | 2006-08-09 | 2008-02-21 | Biogen Idec Ma Inc. | Method for distribution of a drug |
-
2008
- 2008-06-13 BR BRPI0814252A patent/BRPI0814252B8/pt active IP Right Grant
- 2008-06-13 NZ NZ582436A patent/NZ582436A/en unknown
- 2008-06-13 MX MX2009013593A patent/MX2009013593A/es active IP Right Grant
- 2008-06-13 EP EP08771026.5A patent/EP2170390B1/en active Active
- 2008-06-13 US US12/139,362 patent/US20080311119A1/en not_active Abandoned
- 2008-06-13 AU AU2008266051A patent/AU2008266051B2/en active Active
- 2008-06-13 AR ARP080102545A patent/AR067011A1/es not_active Application Discontinuation
- 2008-06-13 SI SI200832029T patent/SI2170390T1/sl unknown
- 2008-06-13 TW TW097122335A patent/TWI614028B/zh active
- 2008-06-13 JP JP2010512385A patent/JP2010529999A/ja active Pending
- 2008-06-13 CN CN201410163087.4A patent/CN103977404A/zh active Pending
- 2008-06-13 HR HRP20182146TT patent/HRP20182146T1/hr unknown
- 2008-06-13 PL PL08771026T patent/PL2170390T3/pl unknown
- 2008-06-13 PT PT08771026T patent/PT2170390T/pt unknown
- 2008-06-13 CN CN200880102434A patent/CN101778640A/zh active Pending
- 2008-06-13 DK DK08771026.5T patent/DK2170390T3/en active
- 2008-06-13 ES ES08771026T patent/ES2707815T3/es active Active
- 2008-06-13 LT LTEP08771026.5T patent/LT2170390T/lt unknown
- 2008-06-13 EA EA201070015A patent/EA020456B1/ru unknown
- 2008-06-13 CA CA2690382A patent/CA2690382A1/en not_active Abandoned
- 2008-06-13 WO PCT/US2008/066928 patent/WO2008157356A2/en not_active Ceased
- 2008-06-13 TR TR2018/20837T patent/TR201820837T4/tr unknown
- 2008-06-13 HU HUE08771026A patent/HUE041555T2/hu unknown
- 2008-06-13 NZ NZ595526A patent/NZ595526A/xx unknown
- 2008-06-13 EP EP18193307.8A patent/EP3461500A1/en active Pending
-
2009
- 2009-12-10 IL IL202648A patent/IL202648B/en active IP Right Grant
- 2009-12-11 MX MX2020005214A patent/MX2020005214A/es unknown
-
2012
- 2012-01-27 US US13/359,959 patent/US20120134989A1/en not_active Abandoned
- 2012-06-22 US US13/530,879 patent/US9533044B2/en active Active
-
2013
- 2013-09-04 JP JP2013182749A patent/JP2014040424A/ja active Pending
-
2019
- 2019-02-01 CY CY20191100146T patent/CY1121208T1/el unknown
- 2019-03-19 AR ARP190100691A patent/AR117403A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2690382A1 (en) | Antibody formulations | |
| US20100181491A1 (en) | Digitizer for a digital imaging system | |
| US10716522B2 (en) | Radiation image capturing apparatus, radiation image capturing system, and method of controlling radiation image capturing apparatus | |
| CN103083029B (zh) | 光子计数检测器以及光子计数和检测方法 | |
| EP3349434B1 (en) | Radiation imaging apparatus and radiation imaging system | |
| US9897707B2 (en) | X-ray detector operable in a mixed photon-counting/analog output mode | |
| EP2203762B1 (en) | Particle-counting apparatus with pulse shortening | |
| CN101529274B (zh) | 用于探测x射线辐射的装置、成像设备和方法 | |
| US8866094B2 (en) | Radiation detector | |
| US20160241795A1 (en) | Image-capturing device, radiation detection apparatus, and control method for image-capturing device | |
| CN102577122A (zh) | 用以处理通过辐射探测器所传递的信号的装置 | |
| US20180364373A1 (en) | Counting and integrating pixels, detectors, and methods | |
| CA2535490A1 (en) | Multi-mode digital imaging apparatus and system | |
| CN102955167A (zh) | 用于区分多能带辐射中的光子的能带的设备和方法 | |
| WO2010107981A1 (en) | Method of high-energy particle imaging by computing a difference between sampled pixel voltages | |
| EP2353032B1 (en) | Analog silicon photomultiplier using phase detection | |
| WO2008054883A9 (en) | Devices and methods for detecting and analyzing radiation | |
| CN117157556A (zh) | 基线恢复器电路 | |
| Adachi et al. | Noise properties of a Se-based flat-panel x-ray detector with CMOS readout integrated circuits | |
| EP3756033B1 (en) | Method of reading out data in a radiation detector, radiation detector and imaging apparatus | |
| US11812187B2 (en) | Combined imaging array and strip | |
| US11750944B2 (en) | Pixel noise cancellation system | |
| US12360258B2 (en) | Radiation image sensor | |
| CN100530664C (zh) | 多模式数字成像装置和系统 | |
| CN119902254B (zh) | 光子探测单元、成像探测阵列、x射线成像探测模块、探测器和探测系统 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20130523 |
|
| FZDE | Discontinued |
Effective date: 20161208 |